natgillin/translations-raw huggingface dataset:
However in DTC patients with low body weight ( &lt; 60 kg) had a higher incidence of PPE, proteinuria, of Grade 3 or 4 hypocalcaemia and hyponatraemia, and a trend towards a higher incidence of Grade 3 or 4 decreased appetite.
Međutim, u slučaju diferenciranog karcinoma štitnjače, bolesnici male tjelesne težine ( &lt; 60 kg) imali su višu incidenciju PPE-a, proteinurije, 3. ili 4. stupnja hipokalcemije i hiponatremije te sklonost prema višoj incidenciji smanjenog apetita 3. ili 4. stupnja.
However patients with hepatic impairment such as bilirubin &gt; 1.5 times the upper limit of normal and/or aminotransferase &gt; 3.0 times the upper limit of normal (hepatic metastases absent) or &gt; 5.0 times the upper limit of normal (hepatic metastases present) have not been specifically studied.
Međutim, nisu posebno ispitivani bolesnici s oštećenjem jetre u kojih je vrijednost bilirubina bila &gt; 1,5 puta iznad gornje granice normale i/ili vrijednost aminotransferaza &gt; 3,0 puta iznad gornje granice normale (bez metastaza u jetri) odnosno &gt; 5,0 puta iznad gornje granice normale (uz metastaze u jetri).
However patients with hepatic impairment such as bilirubin &gt; 1.5 times the upper limit of normal and/or aminotransferase &gt; 3.0times the upper limit of normal (hepatic metastases absent) or &gt; 5.0 times the upper limit of normal (hepatic metastases present) have not been specifically studied.
Međutim, nisu posebno ispitivani bolesnici s oštećenjem jetre u kojih je vrijednost bilirubina bila &gt; 1,5 puta iznad gornje granice normale i/ili vrijednost aminotransferaza &gt; 3,0 puta iznad gornje granice normale (bez metastaza u jetri) odnosno &gt; 5,0 puta iznad gornje granice normale (uz metastaze u jetri).
However the potential absorption and accumulation of sevelamer during long-term chronic treatment ( &gt; one year) cannot be totally excluded (see section 5.2).
Međutim, ne može se potpuno isključiti mogućnost apsorpcije i akumulacije sevelamera tijekom dugotrajnog kroničnog liječenja (dulje od godine dana) (vidjeti dio 5.2).
However, 1,611 patients (804 bosentan- and 807 placebo-treated patients) with severe chronic heart failure (CHF) were treated for a mean duration of 1.5 years in a placebo- controlled study (study AC-052-301/302 [ENABLE 1 &amp; 2]).
Međutim, na 1611 bolesnika (804 je dobivalo bosentan, a 807 placebo) s teškim kroničnim zatajenjem srca provedena je placebom kontrolirana studija u prosječnom trajanju od 1,5 godine (studija AC-052-301/302 [ENABLE 1 &amp; 2]).
However, 1,611 patients (804 bosentan- and 807 placebo-treated patients) with severe chronic heart failure (CHF) were treated for a mean duration of 1.5 years in a placebo-controlled study (study AC-052-301/302 [ENABLE 1 &amp; 2]).
Međutim, na 1611 bolesnika (804 je dobivalo bosentan, a 807 placebo) s teškim kroničnim zatajenjem srca provedena je placebom kontrolirana studija u prosječnom trajanju od 1,5 godine (studija AC-052-301/302 [ENABLE 1 &amp; 2]).
However, a higher percentage of subjects in the cobicistat-boosted group had increases in total bilirubin &gt; 2 x ULN than those in the ritonavir-boosted group (88.0% versus 80.9%).
Međutim, veći postotak ispitanika u skupini koja je primala kobicistatom pojačani lijek je imalo povećanja u ukupnom bilirubinu &gt; 2 x GGN, nego oni u skupini koja je primala ritonavirom pojačani lijek (88,0% naspram 80,9%).
However, a post-exposure interval &gt; 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.
Ipak, vremenski interval veći od 1 sata nakon izlaganja ne isključuje davanje i učinkovitost sredstva za kelaciju koja je u tom slučaju smanjena.
However, a post-exposure interval &gt; 1 hour does not preclude the administration and effective action of chelator, even if with reduced efficiency.
Međutim, izloženost radionuklidu dulje od jednog sata ne isključuje primjenu kelirajuće terapije i njeno učinkovito djelovanje, čak i ako uz smanjenu učinkovitost.
However, a post-exposure interval &gt; 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.
Ako je interval nakon ekspozicije duži od 1 sata, to ne isključuje primjenu niti učinkovitost kelata, iako je njihov učinak tada slabiji.
However, a post-exposure interval &gt; 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.
Međutim, razdoblje dulje od jednog sata nakon izlaganja ne isključuje primjenu i učinkovitost pripravka za kelaciju, koja je u tom slučaju smanjena.
However, a slight increase in abortion/embryonal-foetal death was observed with high systemic exposure ( &gt; 100 x human exposure) in the 50 mg/kg/day high-dose group compared to placebo and other low-dose groups.
Međutim, primijećeno je blago povišenje u stopi pobačaja/smrti embrija ili fetusa uz visoku sistemsku izloženost ( &gt; 100 x ljudske izloženosti) u skupini koja je primala visoku dozu od 50 mg/kg/dan u usporedbi sa skupinama koje su primale placebo odnosno nisku dozu.
However, an evaluation with 50 mg opicapone was performed in subjects included in both phase 3 studies with GFR/1.73 m2 &lt; 60 mL/min (i.e. moderately decreased renal elimination capacity), and using pooled BIA 9-1103 data (major metabolite of opicapone).
Međutim, napravljena je procijena primjene 50 mg opikapona u ispitanika uključenih u oba ispitivanja faze 3 s brzinom glomerularne filtracije od &lt; 60 ml/min/1,73 m2 (tj. umjereno oslabljene sposobnosti bubrežne eliminacije), korištenjem objedinjenih podataka za BIA 9-1103 (glavni metabolit opikapona).
However, at high MPAG plasma concentrations ( &gt; 100 µg/mL), small amounts of MPAG are removed.
Međutim, pri visokim koncentracijama MPAG-a u plazmi ( &gt; 100 µg/ml) uklonjene su male količine MPAG-a.
However, at high MPAG plasma concentrations ( &gt; 100µg/mL), small amounts of MPAG are removed.
Međutim, pri visokim koncentracijama MPAG-a u plazmi ( &gt; 100µg/ml) uklonjene su male količine MPAG-a.
However, at high MPAG plasma concentrations ( &gt; °100 g/mL), small amounts of MPAG are removed.
Međutim, pri visokim koncentracijama MPAG-a u plazmi ( &gt; 100 µg/ml) uklonjene su male količine MPAG-a.
However, at high MPAG plasma concentrations ( &gt; °100°g/mL), small amounts of MPAG are removed.
Međutim, pri visokim koncentracijama MPAG-a u plazmi ( &gt; 100 µg/ml) uklonjene su male količine MPAG-a.
However, at high MPAG plasma concentrations ( &gt; °100°g/mL), small amounts of MPAG are removed.
Međutim, pri visokim koncentracijama MPAG-a u plazmi ( &gt; 100µg/ml) uklonjene su male količine MPAG-a.
However, clinical experience in patients &gt; 80 years of age is limited and caution should be exercised when treating this population.
Međutim, kliničko iskustvo kod bolesnika &gt; 80 godina starosti je ograničeno te je potreban oprez u liječenju ove populacije.
However, data in the age group 2 months to &lt; 3 years (9 patients) is limited (see section 5.1).
Ipak, podaci o dobnoj skupini od 2 mjeseca do &lt; 3 godine (9 bolesnika) su ograničeni (vidjeti dio 5.1).
However, during the period of administration of filgrastim for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/L.
Međutim, tijekom razdoblja primjene filgrastima za mobilizaciju progenitorskih stanica periferne krvi, potrebno je prekinuti primjenu ili smanjiti dozu filgrastima ako se broj leukocita poveća na &gt; 70 x 109/l.
However, during the period of administration of filgrastim for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/L.
Međutim, tijekom razdoblja primjene filgrastima za mobilizaciju stanica preteča periferne krvi, potrebno je prekinuti primjenu ili smanjiti dozu filgrastima ako se broj leukocita poveća na &gt; 70 x 109/l.
However, during the period of administration of filgrastim for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/L.
No daje li se filgrastim za mobilizaciju progenitorskih stanica periferne krvi, treba ga obustaviti, ili njegovu dozu smanjiti ako broj leukocita dosegne vrijednost &gt; 70 x 109/l.
However, during the period of administration of filgrastim for PBPC mobilisation, it should be discontinued or its dosage should be reduced if the leukocyte counts rise to &gt; 70 x 109/l.
Međutim, ako se tijekom razdoblja primjene filgrastima za mobilizaciju progenitorskih stanica iz periferne krvi broj leukocita poveća na vrijednosti &gt; 70 x 109/l, potrebno je prekinuti primjenu ili smanjiti dozu filgrastima.
However, elderly patients ( &gt; 70 years of age) appear to be at increased risk of neutropenia and thrombocytopenia (see section 4.4).
Ipak, čini se da je u starijih bolesnika ( &gt; 70 godina) povećan rizik od razvoja neutropenije i trombocitopenije (vidjeti dio 4.4).
However, for patients with a body surface area &gt; 0.38 m2, the contents of between 1 to 7 vials will be required to produce the recommended daily dosage of clofarabine.
Međutim, u bolesnika s površinom tijela &gt; 0,38 m2 za postizanje preporučene dnevne doze klofarabina bit će potreban sadržaj od 1 do 7 bočica.
However, if the haemoglobin has increased &lt; 1 g/dl ( &lt; 0.62 mmol/l) and the reticulocyte count has increased &lt; 40 000 cells/µl above baseline, response is unlikely and treatment should be discontinued.
Međutim, ukoliko se hemoglobin poveća za &lt; 1 g/dl (0,62 mmol/l) ili se broj retikulocita poveća za &lt; 40 000 stanica/µl iznad početne vrijednosti, terapiju treba prekinuti jer nije vjerojatno da će doći do odgovora.
However, in clinical studies to date, dizziness and somnolence were associated infrequently ( &lt; 5%) with the administration of Caelyx.
Međutim, u do sada provedenim kliničkim ispitivanjima omaglica i pospanost nisu bile često povezane ( &lt; 5%) s primjenom lijeka Caelyx.
However, in field studies 10% of sero-negative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Međutim, u terenskim istraživanjima 10% seronegativnih pasa nije pokazalo serokonverziju ( 0,1 I.J./ml) 3 – 4 tjedna nakon jednog osnovnog cijepljenja protiv bjesnoće.
However, in field studies 10% of sero-negative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Međutim, u terenskim istraživanjima 10% seronegativnih pasa nije pokazalo serokonverziju ( 0.1 I.J./ml) 3 – 4 tjedna nakon jednog osnovnog cijepljenja protiv bjesnoće.
However, in field studies 10% of sero-negative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Međutim, u terenskom ispitivanju 10% seronegativnih pasa nije pokazalo serokonverziju ( &gt; 0,1 IJ/ml) 3 - 4 tjedna nakon prvog osnovnog cijepljenja protiv bjesnoće.
However, in field studies 10% of sero-negative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Međutim, u terenskom ispitivanju 10% seronegativnih pasa nije pokazalo serokonverziju ( &gt; 0,1 IJ/ml) 3-4 tjedna nakon prvog osnovnog cijepljenja protiv bjesnoće.
However, in field studies 10% of seronegative dogs did not show seroconversion ( &gt; 0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies.
Međutim, u terenskom ispitivanju 10% seronegativnih pasa nije pokazalo serokonverziju ( &gt; 0,1 IJ/ml) 3 - 4 tjedna nakon prvog osnovnog cijepljenja protiv bjesnoće.
However, in patients with liver iron concentration &lt; 7 mg Fe/g dw treated with deferasirox dispersible tablets (5 and 10 mg/kg) or deferoxamine (20 to 35 mg/kg), non-inferiority was not established due to imbalance in the dosing of the two chelators.
Međutim, u bolesnika s koncentracijom željeza u jetri &lt; 7 mg Fe/g suhe težine liječenih deferasiroks tabletama za oralnu suspenziju (5 i 10 mg/kg) ili deferoksaminom (20 do 35 mg/kg) neinferiornost nije potvrđena zbog neravnoteže u doziranju dvaju kelatora.
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but &lt; 60 ml/min) this fixed dose combination should be administered with caution.
Međutim kombinaciju fiksne doze treba oprezno primjenjivati u bolesnika koji imaju blago do umjereno oštećenom funkciju bubrega (klirens kreatinina ≥ 30 ml/min, ali &lt; 60 ml/min).
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but &lt; 60 ml/min) this fixed dose combination should be administered with caution.
Međutim kombinaciju fiksne doze treba oprezno primjenjivati u bolesnika koji imaju blago do umjereno oštećenu funkciju bubrega (klirens kreatinina ≥ 30 ml/min, ali &lt; 60 ml/min).
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but &lt; 60 ml/min) this fixed dose combination should be administered with caution.
Međutim, kombinaciju fiksne doze treba oprezno primjenjivati u bolesnika koji imaju blago do umjereno oštećenom funkciju bubrega (klirens kreatinina ≥ 30 ml/min, ali &lt; 60 ml/min).
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but &lt; 60 ml/min) this fixed dose combination should be administered with caution.
Međutim, kombinaciju fiksne doze treba oprezno primjenjivati u bolesnika koji imaju blago do umjereno oštećenu funkciju bubrega (klirens kreatinina ≥ 30 ml/min, ali &lt; 60 ml/min).
However, in patients with mild to moderate renal impairment (creatinine clearance ≥30 ml/min but &lt; 60 ml/min) this fixed dose combination should be administered with caution.
Međutim, kombinaciju fiksne doze treba oprezno primjenjivati u bolesnika koji imaju blago do umjereno oštećenu funkciju bubrega (klirens kreatinina ≥ 30 ml/min, ali &lt; 60 ml/min).
However, in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) or end-stage renal disease requiring haemodialysis or peritoneal dialysis, bedaquiline concentrations may be increased due to alteration of active substance absorption, distribution, and metabolism secondary to renal dysfunction.
Međutim, u bolesnika s teškim oštećenjem bubrega (klirens kreatinina &lt; 30 ml/min) ili završnim stadijem bubrežne bolesti koje zahtijeva hemodijalizu ili peritonealnu dijalizu, koncentracije bedakilina mogu biti povišene zbog izmjene apsorpcije djelatne tvari, distribucije i metabolizma kao posljedica bubrežne disfunkcije.
However, patients with hepatic impairment, such as bilirubin &gt; 1.5-times the upper limit of normal and/or aminotransferase &gt; 3.0-times the upper limit of normal (hepatic metastases absent) or &gt; 5.0-times the upper limit of normal (hepatic metastases present), have not been specifically studied.
Međutim, nisu posebno ispitivani bolesnici s oštećenjem jetre u kojih je vrijednost bilirubina bila &gt; 1,5 puta iznad gornje granice normale i/ili vrijednost aminotransferaza &gt; 3,0 puta iznad gornje granice normale (bez metastaza u jetri) odnosno &gt; 5,0 puta iznad gornje granice normale (uz metastaze u jetri).
However, post-exposure prophylaxis for varicella and measles has been demonstrated with Varicella Vaccine live (Oka/Merck) and the measles-containing vaccines manufactured by Merck &amp; Co., Inc., respectively.
Međutim, pokazalo se da živo cjepivo protiv varičele (Oka/Merck) pruža profilaksu protiv varičele nakon izlaganja i da cjepiva proizvođača Merck &amp; Co., Inc. koja sadrže virus morbila pružaju profilaksu protiv morbila nakon izlaganja.
However, since M-M-RVAXPRO has been shown to have safety and immunogenicity profiles similar to the previous formulation of the combined measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc., experience with this vaccine can be considered.
Međutim, kako se pokazalo da M-M-RVAXPRO ima sigurnosni i imunogeni profil sličan prethodnom kombiniranom cjepivu protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc., može se uzeti u obzir iskustvo s tim cjepivom.
However, systemic absorption of topically applied olopatadine is minimal with plasma concentrations ranging from below the assay quantitation limit ( &lt; 0.5 ng/ml) up to 1.3 ng/ml.
Međutim, sustavna apsorpcija topikalno primijenjenog olopatadina je minimalna te se koncentracije u plazmi kreću od one koja je ispod donje granice osjetljivosti testa ( &lt; 0,5 ng/ml) do 1,3 ng/ml.
However, the combination product is not recommended for patients with severe renal impairment (creatinine clearance &lt; 30 mL/minute).
No kombinirani lijek se ne preporučuje bolesnicima s teško oštećenom bubrežnom funkcijom (klirens kreatinina &lt; 30 ml/min).
However, the efficacy of Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. has been demonstrated in numerous studies.
Međutim, brojna druga ispitivanja pokazala su djelotvornost živog cjepiva protiv varičele (Oka/Merck) i cjepiva protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc.
However, the incidences of decreases in serum calcium to &lt; 8.0 mg/dl (2.0 mmol/l) and serum phosphate to  2.0 mg/dl (0.65 mmol/l) were similar in both treatment groups.
Incidencije sniženja serumskog kalcija na &lt; 8,0 mg/dl (2,0 mmol/l) i serumskog fosfata na  2,0 mg/dl (0,65 mmol/l) bile su slične u obje ispitivane skupine.
However, the marketing authorisation holder shall submit periodic safety update reports for this medicinal product if the product is included in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Nositelj odobrenja će periodička izvješća o neškodljivosti podnositi ako je lijek uvršten u referentni popis datuma EU (EURD popis) predviđenim člankom 107(c) stavkom 7 Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove. &gt;
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC &lt; 1.0 x 109/l) and thrombocytopenias (platelet count
Međutim, pojava citopenija također je jasno ovisila o fazi bolesti, kod čega je incidencija neutropenija stupnja 3 i 4 (ABN &lt; 1,0 x 109/l) i trombocitopenija (broj trombocita &lt; 50 x 109/l) bila između 4 i
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC &lt; 1.0 x 109/l) and thrombocytopenias (platelet count &lt; 50 x 109/l) being between 4 and 6 times higher in blast crisis and accelerated phase (59-64% and 44-63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia).
Međutim, pojava citopenija također je jasno ovisila o fazi bolesti, kod čega je incidencija neutropenija i 4. stupnja (ABN &lt; 1,0 x 109/l) i trombocitopenija (broj trombocita &lt; 50 x 109/l) bila između 4 i 6 puta veća u blastičnoj krizi i ubrzanoj fazi (59-64% i 44-63% za neutropeniju odnosno trombocitopeniju) u usporedbi s novodijagnosticiranim bolesnicima u kroničnoj fazi KML-a (16,7% neutropenija i 8,9% trombocitopenija).
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC &lt; 1.0 x 109/l) and thrombocytopenias (platelet count &lt; 50 x 109/l) being between 4 and 6 times higher in blast crisis and accelerated phase (59–64 % and 44–63 % for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7 % neutropenia and 8.9 % thrombocytopenia).
Međutim, pojava citopenija također je jasno ovisila o fazi bolesti, kod čega je učestalost neutropenija 3. ili 4. stupnja (ABN &lt; 1,0 x 109/l) i trombocitopenija (broj trombocita &lt; 50 x 109/l) bila između 4 i 6 puta veća u blastičnoj krizi i ubrzanoj fazi (59–64 % za neutropeniju i 44–63 % za trombocitopeniju) u usporedbi s novodijagnosticiranim bolesnicima u kroničnoj fazi KML-a (16,7 % neutropenija i 8,9 % trombocitopenija).
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC &lt; 1.0 x 109/L) and thrombocytopenias (platelet count &lt; 50 x 109/L) being between 4 and 6 times higher in blast crisis and accelerated phase (59–64% and 44–63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia).
Međutim, pojava citopenija također je jasno ovisila o fazi bolesti, kod čega je učestalost neutropenija stupnja 3 i 4 (ABN &lt; 1,0 x 109/l) i trombocitopenija (broj trombocita &lt; 50 x 109/l) bila između 4 i 6 puta veća u blastičnoj krizi i ubrzanoj fazi (59-64% za neutropeniju, odnosno 44-63% za trombocitopeniju) u usporedbi s novodijagnosticiranim bolesnicima u kroničnoj fazi KML-a (16,7% neutropenija i 8,9% trombocitopenija).
However, thoughts of harming others, physical assault or threatening behaviour were observed in some patients ( &lt; 1% in perampanel clinical studies).
Međutim, u nekih je bolesnika opažena pojava misli o ozljeđivanju drugih, fizičkom napadu ili prijeteće ponašanje ( &lt; 1% u kliničkim ispitivanjima perampanela).
HR Hazard ratio (hazard ratios &lt; 1 favour IRESSA)
HR Omjer hazarda (omjer hazarda &lt; 1 ide u korist lijeka IRESSA)
HRb (95% CI)=0.63 (0.50; 0.79) p-valued &lt; 0.001
HRb (95 % CI)=0,63 (0,50; 0,79) p-vrijednostd &lt; 0,001
HRb (95% CI)=0.63 (0.50; 0.79) p-valued &lt; 0.001
HRb (95% CI) = 0,63 (0,50; 0,79) p-vrijednostd &lt; 0,001
HRb (95% CI)=0.63 (0.50; 0.79) p-valued &lt; 0.001
HRb (95% CI)=0,63 (0,50; 0,79) p-vrijednostd &lt; 0,001
Human plasma protein binding of netupitant and its two major metabolites M1 and M3 is &gt; 99% at concentrations ranging from 10 to 1500 ng/mL.
Vezanje netupitanta te njegovih dvaju glavnih metabolita M1 i M3 na proteine u ljudskoj plazmi iznosi &gt; 99% pri koncentracijama u rasponu od 10 do 1500 ng/ml.
Humira/methotrexate combination therapy was clinically and statistically superior to methotrexate (p &lt; 0.001) and Humira monotherapy (p &lt; 0.001) in achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis.
Kombinirana primjena lijeka Humira i metotreksata pokazala se klinički i statistički superiornom monoterapiji metotreksatom (p &lt; 0,001) i lijekom Humira (p &lt; 0,001) u postizanju niske aktivnosti bolesti u bolesnika s nedavno dijagnosticiranim umjerenim do teškim reumatoidnim artritisom.
HVL ( &gt; 600,000
17,8; 26,0
HVL ( &gt; 600,000
48,6; 62,0
Hypercalcaemia &gt; 12 mg/dl (2.99 mmol/l).
Hiperkalcemija &gt; 12 mg/dl (2,99 mmol/l).
Hyperkalaemia, hyponatremia or Na⁺/K⁺ ratio &lt; 27: Decrease the Zycortal dosing interval by 2–3 days or increase the dose.
Hiperkalemia, hiponatremija ili omjer Na⁺/K⁺ &lt; 27: smanjite interval doziranja Zycortala za 2 do 3 dana ili povećajte dozu.
Hypersensitivity reactions have been reported in &lt; 1% of patients treated with dolutegravir in clinical studies, and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including severe liver reactions.
U &lt; 1% bolesnika liječenih dolutegravirom u kliničkim ispitivanjima prijavljene su reakcije preosjetljivosti koje su se manifestirale osipom, općim simptomima te ponekad poremećajem funkcije organa, uključujući teške jetrene reakcije.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Docetaxel must not be used in patients with baseline neutrophil count of &lt; 1,500 cells/mm3.
Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1. Bolesnici s početnim brojem neutrofila  1500 stanica/mm3.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with baseline neutrophil count of &lt; 1,500 cells/mm3.
Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1. Bolesnici s početnim brojem neutrofila  1500 stanica/mm3.